Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/29/23 | $10,000,000 | Series A |
Clarke Capital Partners | undisclosed |
